Full TitleA Pilot Study of Durvalumab (Medi4736) with Tremelimumab in Combination with Image Guided Stereotactic Body Radiotherapy (SBRT) in the Treatment of Metastatic Anaplastic Thyroid Cancer
Durvalumab and tremelimumab are immunotherapy drugs. They boost the power of the immune system to recognize and kill cancer cells by inhibiting proteins that normally put the brakes on the immune response. Durvalumab targets the PD-L1 protein, while tremelimumab inhibits the CTLA-4 protein.
In this study, researchers are assessing the safety and effectiveness of giving these two drugs together with stereotactic body radiation therapy (a very focused treatment with high-dose radiation) in patients with metastatic anaplastic thyroid cancer. Combining immunotherapy with radiation may further enhance the immune response against thyroid cancer.
Durvalumab is approved for treating advanced bladder cancer; its use in this study is considered investigational. Tremelimumab is an investigational drug. Both medications are given intravenously (by vein).
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have metastatic anaplastic thyroid cancer that cannot be cured with surgery or radiation therapy.
- At least 1 week must pass between the completion of prior treatment and entry into the study.
- Patients may not have previously received immunotherapies that target PD-L1, PD-1, or CTLA-4.
- Patients must be able to walk and do routine activities for more than half of their normal waking hours.
- This study is open to patients age 18 and older.
For more information about this study and to inquire about eligibility, please contact Dr. Nancy Lee at 212-639-3341.